blog
Last updated: 2017-06-06

Mesothelioma Clinical Trial Information: Immune Checkpoint Inhibitors and Targeted Therapies in Japan

S
Medical Supporter Team
Cross-border medical coordination and editorial review team
Mesothelioma Clinical Trial Information: Immune Checkpoint Inhibitors and Targeted Therapies in Japan

Mesothelioma Clinical Trial Information: Immune Checkpoint Inhibitors and Targeted Therapies in Japan

Medical Supporter — Information Notice

This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.

Any specific treatment plan must be assessed by a licensed physician in Japan
  • March 10, 2016
  • 1 min read

Below is a summary of clinical trial information relevant to mesothelioma and rare cancer sites in Japan, provided for patient reference.

1. Phase 2 Safety Trial of PD-1 Immune Checkpoint Inhibitor for Rare Cancer Sites (Anal Cancer, Cholangiocarcinoma, Thyroid Cancer)

https://clinicaltrials.gov/ct2/show/NCT02628067

2. Gene Therapy: Clinical Trial Using Ad-SGE-REIC

A clinical trial using the gene therapy agent Ad-SGE-REIC, conducted at Okayama University.

3. Cancer Stem Cell Inhibitor BBI608 Phase 1/2 Trial

A Phase 1/2 clinical trial using BBI608, a cancer stem cell-targeting agent characterized by STAT3 inhibition. The trial is divided into two parts.

https://clinicaltrials.gov/ct2/show/study/NCT02347917

4. Phase 1 Trial Using BAY94-9343

A Phase 1 clinical trial using BAY94-9343 in patients who have not responded to standard therapy.

https://clinicaltrials.gov/ct2/show/NCT02485119

All four clinical trials include links and site information — please access the links directly for details. We receive many inquiries about rare cancer sites; unlike common sites such as lung and colorectal cancer where data is abundant, rare site data requires additional research and translation time. We apologize for the delay.

Disclaimer: Medical Supporter translates overseas clinical trial data and pharmaceutical information for informational purposes only. This is not an encouragement to enroll in clinical trials or use any specific drugs. If the clinical trial organization has publicly posted contact information, patients may contact them directly. Please contact us if you need assistance.

Mesothelioma | Cholangiocarcinoma | Thyroid Cancer | Anal Cancer

  • Immunotherapy

  • Clinical Trial Medications

    • (Lung Cancer) Phase II results for Topotecan and Topotecan + Berzosertib combination.
    • (Lung Cancer) Efficacy of Enhertu in HER2-mutant non-small cell lung cancer (NSCLC).
    • (Lung Cancer) Clinical outcomes of anti-B7-H3 antibody-drug conjugate DS-7300.

Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).

Considering medical care in Japan? Need information and support?

We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.

Fukuoka HQ: +81-92-409-5655
Formerly officially certified, No. B-066

Figure 1Figure 1

Figure 2Figure 2

Figure 3Figure 3

Figure 4Figure 4

Related Cancer Information

Related Reading